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Background: To evaluate the presence of oral lesions in a group of patients with primary Sjögren’s syndrome 
(pSS) and compare these results with a matched control group (CG).
Material and Methods: An observational cross-sectional study was conducted. 61 pSS patients (60 women, 1 man, 
mean age 57.64±13.52) diagnosed according to the American European Criteria (2002), and 122 matched control 
patients (120 women, 2 men, mean age 60.02±13.13) were included. Demographic and medical data, oral lesions 
and salivary flow rate were collected.
Results: Compared with the controls, pSS patients were 3.95 more likely to have oral lesions (OR 3.95; 95% CI 
2.06-7.58; p=0.0001). 57.4% pSS patients presented oral lesions compared to 25.4% in CG. The most common 
were candidiasis (13.1% vs 2.5%), traumatic lesions (13.1% vs 4.1%), apthae (8.2% vs 0), and fissuration of the 
tongue (8.2% vs 0.8%). pSS patients with oral lesions had lower salivary flow levels (stimulated and unstimulated), 
although these differences were not significant. Significant associations were found between the presence of oral 
lesions and systemic manifestations and history of parotid gland enlargement in pSS patients.
Conclusion: pSS patients suffer more oral lesions than general population and these lesions may aggravate the 
pSS disease.
Key words: Sjögren’s syndrome, oral lesions, oral diseases, oral manifestations, oral disorders.
doi:10.4317/medoral.23254
http://dx.doi.org/doi:10.4317/medoral.23254
Serrano J, López-Pintor RM, Fernández-Castro M, Ramírez L, Sanz M, 
Casañas E, et al. Oral lesions in patients with primary Sjögren’s syn-
drome. A case-control cross-sectional study. Med Oral Patol Oral Cir Bu-
cal. 2020 Jan 1;25 (1):e137-43.
http://www.medicinaoral.com/pubmed/medoralv25_i1_p137.pdf
Article Number: 23254          http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
e138
Med Oral Patol Oral Cir Bucal. 2020 Jan 1;25 (1):e137-43. Oral lesions in primary Sjögren’s syndrome compared to a control group
Introduction
Sjögren syndrome (SS) is a systemic autoimmune exo-
crinopathy of unknown aetiology. Different predispos-
ing factors along with several immune-related processes 
have been described in its pathogenesis, supporting the 
idea of a multifactorial disease (1). It can occur as pri-
mary SS (pSS), when it courses as an isolated disorder 
or as secondary SS when it appears in association with 
another systemic autoimmune disease (2). pSS usually 
emerges in the 4th - 5th decade of life, affecting women 
more than men, in a proportion 9:1, and its prevalence 
rates range between 0.1 to 4.8% (1,3,4). 
pSS is a chronic inflammatory disease characterized 
by lymphocytic infiltration of the lacrimal and salivary 
glands resulting in the primary symptoms of this condi-
tion: presence of dry eyes and hyposalivation. Almost 
half of the patients develop extraglandular manifesta-
tions, such as pulmonary, liver, kidney, vascular sys-
tem, nervous system, respiratory and/or gastrointestinal 
tract involvement (4). Different pSS classification sys-
tems have been published (5), although the most widely 
used has been the proposed by the American-European 
Consensus Group (AECG) in 2002 (6). In 2016, the 
American College of Rheumatology and the European 
League against Rheumatism developed new classifica-
tion criteria replacing the previous ones (7).
Saliva is essential in maintaining oral health. It has im-
portant functions, such as lubrication, buffering, anti-
bacterial/antifungal activity, as well as the facilitation 
of digestion and tooth remineralization. The decrease 
of saliva increases the risk of tooth decay, oral soreness, 
taste alterations and halitosis. It may also increase the 
difficulty in wearing dentures. Painful tongue, fissures 
on the tongue and mucosal ulcers are also common in 
pSS patients (2,8,9,10,11). Only two studies (10,11) have 
reported the prevalence of oral lesions in these patients 
and previous investigations have connected the use of 
dental prosthesis with the presence of oral lesions, es-
pecially candidiasis (9,10,12) but there are no studies 
that relate other predisposing factors such as tobacco 
or alcohol consumption, drug intake, or other systemic 
diseases such as diabetes or hypertension with the pres-
ence of oral lesions in pSS patients. 
Therefore, the main objective of the present study was 
to evaluate the presence of oral lesions in pSS patients 
and to compare with a matched CG. The second goal 
was to study the association between oral lesions and 
different risk factors and pSS variables. 
Material and Methods 
- Study design and patient selection
A cross-sectional case-control study was conducted, 
with an inclusion period of twenty months. The present 
study is part of a project (EPOX-SSp project) studying 
the oral health condition of pSS patients in the Commu-
nity of Madrid (12). All the procedures were carried out 
according to the Declaration of Helsinki and its follow-
ing revision, and the study protocol was approved by 
the Ethical Committee of the University Hospital of La 
Paz, Madrid (no: HULP PI-1891). This study followed 
the STROBE guidelines for reporting.
A consecutive sampling of all pSS patients attending 
different rheumatology services in the region of Madrid 
between October 2015 and June 2017, were invited to 
participate. These inclusion criteria included being over 
18 years old and having the diagnosis of pSS accord-
ing to the diagnostic criteria proposed by the AECG (6). 
Subjects were excluded when the selected patient pre-
sented physical or psychological difficulties to attend 
the School of Dentistry or with a history of systemic au-
toimmune connective tissue disease (apart from pSS). 
A rheumatologist initially evaluated the inclusion and 
exclusion criteria and registered the demographic and 
pSS characteristics, including the time from diagnosis, 
serological data (rheumatoid factor, immunoglobulins 
alteration, antinuclear autoantibodies), and systemic 
manifestations of pSS (parotid enlargement, muscu-
loskeletal, skin, lung, renal, central nervous system, 
peripheral nervous system, haematological, gastroin-
testinal or cardiac involvement). Selected patients were 
then instructed to contact the Oral Medicine Postgradu-
ate Program at the Faculty of Odontology in the Com-
plutense University of Madrid for an oral examination. 
The matched CG consisted of consecutive patients with 
similar age and gender, who attended a primary physi-
cian consultation for routine medical check-ups at dif-
ferent Health Centers of the Region of Madrid, but not 
in relation with any oral pathology. Exclusion criteria 
for CG were patients in treatment with corticosteroids, 
antifungal or antibiotic agents, and/or with history of 
systemic autoimmune connective tissue disease.
- Variables and data sources
At the Faculty of Odontology, all demographic data (age 
and gender), medical history, drugs (type and number 
of medicines), alcohol intake, tobacco consumption and 
dose as well as presence and type of dentures were re-
corded in both groups. A complete oro-facial examina-
tion was carried out by a specialist in oral medicine (JS), 
focused on detecting parotid gland enlargement and in-
traoral mucosal or oral lesions. To diagnose oral lesions 
the WHO guidelines were followed (13) recording the 
number, type of lesion, location, size, clinical appear-
ance, time of evolution and signs and symptoms. 
Collection of stimulated (SWS) and unstimulated saliva 
(UWS) was performed in pSS patients by one special-
ist in oral medicine (LR). Appointments were between 
8.00 and 10.00 am, and patients were asked not to brush 
their teeth, eat, drink or smoke for at least 90 minutes 
prior to the appointment. UWS was always collected 
first by drooling for 15 minutes. Patients were told to 
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be relaxed, and to keep the mouth slightly open and not 
to swallow. To collect SWS patients were given a par-
affin gum and asked to chew it and continuously spit 
out the saliva into a plastic container for 10 minutes. 
The flow rates were recorded as ml/min. Hyposaliva-
tion was defined as a flow rate <0.7ml/min for SWS and 
<0.1ml/min for UWS. Additionally, each patient in the 
pSS group was asked if they had dry mouth sensation, 
dysphagia and alteration in taste or pain in the tongue.
- Data Analysis. Sample size
The sample size was calculated considering the data on 
prevalence of oral lesions (61.2%) in pSS patients re-
ported by Likar-Manookin et al., Since this study did 
not compare OLs with a CG, we used the percentage of 
OLs of the CG of the study of López-Pintor et al., (14) 
which compared the presence of OLs in renal transplant 
patients with a CG (23.4%) using the same methodol-
ogy. Using an α=0.05 and a statistical power of 95%, 41 
subjects were needed in each group. 
- Data Analysis. Observational Study
Categorical variables were presented as numbers and 
percentages while quantitative variables as means ± 
standard deviation (SD). Kolmogorov-Smirnoff test was 
applied to establish the goodness of fit to normality for 
the variables studied. To determine differences of cat-
egorical variables between the two groups chi-squared 
test or Fisher’s exact test were used. Differences of 
quantitative variables between CG and pSS group were 
compared by the t-student test. U Mann-Whitney test 
was used to determine the possible relationship between 
pSS intragroup quantitative variables and the presence 
of oral lesions. To identify statistically significant as-
sociation between oral lesions and pSS binary logistic 
regression was applied. From this analysis, odds ratio 
(OR) with 95% Confidence Interval (CI) was presented 
with the associated p-value. Differences were consid-
ered significant if p was ≤ than 0.05.
Results 
All demographic data from the selected patients are 
depicted in Table 1. Sixty-seven patients diagnosed 
with possible pSS were evaluated at the oral medicine 
clinic in the Complutense University. Among them, 61 
patients (60 women and 1 man, mean age 57.64±13.52 
years) fulfilled the inclusion criteria proposed by the 
AECG in 2002. One hundred twenty-two CG patients 
(120 women and 2 men, 60.02±13.13 years) were in-
cluded.
Table 2 depicts the characteristics of pSS patients, ac-
cording with the 2002 AECG. pSS systemic manifesta-
tions were also recorded and expressed as number and 
percentage.
- Oral lesions in pSS and CG
Compared with the control group, pSS patients were 3.95 
more likely to have oral lesions (OR 3.95; 95% CI 2.06-
Table 1: pSS and CG patients demographic data.
Variable pSS (n=61) CG (n=122) p
Age (years) 57.64±13.52 60.02±13.13 0.98a
Gender
Male 1 (1.6%) 2 (1.6%) 1c
Female 60 (98.4%) 120 (98.4%) 1c
Tobacco 
Active smokers 8 (13.1%) 16 (13.1%) 1b
Number cigarettes/day 0.75±3.05 1.44±5.67 0.84a
Diabetes patients 3 (4.9%) 6 (4.9%) 1b
Alcohol 13 (21.3%) 26 (21.3%) 1b
Antidepressant 
treatment
7 (11.5%) 14 (11.5%) 1b
Antihypertensive 
treatment
12 (19.7%) 24 (19.7%) 1b
Xerostomia inducing 
drugs
17 (27.9%) 25 (20.5%) 0.27c
Number of drugs 2.91±2.51 0.37±0.54 0.001a
Patients with 
dentures
13 (21.3%) 26 (21.3%) 1b
Acrylic denture 5 (8.2%) 12 (9.8%) 0.16b
Metallic denture 5 (8.2%) 14 (11.5%) 0.16b
Acrylic and metallic 
denture
1 (1.6%) 0 0.16b
Implant-supported 
denture
2  (3.3%) 0 0.16b
Values are number (%) and mean ± standard deviation (SD). Statisti-
cal test: aT-student test, b Fisher’s exact test and cChi-squared test.
7.58; p=0.0001). A 57.4% of pSS patients had some type 
of oral lesion vs. 25.4% of CG patients (p=0.0001). The 
mean number of oral lesions was 0.75±0.79 in the study 
group and 0.27±0.51 in the CG (p=0.0001). Twenty-
one different types of lesions were recorded. The most 
common in both pSS and CG were candidiasis (13.1% 
vs. 2.5%, p=0.007), traumatic lesions (13.1% vs. 4.1% 
p=0.03), apthae (8.2% vs. 0%, p=0.004), and grooves 
or fissuration of the tongue (8.2% vs. 0.8% p=0.02%). 
The most frequent type of oral candidiasis was denture 
stomatitis (8.2% vs. 1.6%, p=0.04) (Table 3).
- Oral lesions and clinical pSS variables 
In pSS group, a significant relationship was found be-
tween the presence of systemic manifestations associ-
ated to pSS, and the appearance of oral lesions. 69.7% of 
pSS patients with systemic manifestation of the disease 
suffered oral lesions (p=0.03). Additionally, 75% of pSS 
patients who had had history of parotid enlargement 
presented oral lesions (p=0.05) (Table 2).
- Oral lesions and salivary flow rates in pSS
Table 4 shows the relationship between the presence 
of oral lesions and UWS and SWS flow rates and 
hyposalivation. pSS patients with oral lesions suffered 
more UWS and SWS hyposalivation and had lower 
UWS and SWS flow rates compared with those without 
oral lesions, but no significant associations were found.
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pSS characteristics Patients with (n / %) Of which oral lesions P
Oral symptoms 59 (96.7%) 33 (55.9%) 0.5c
Ocular symptoms 61 (100%) 35 (57.4%) -
Oral signs 32 (52.5%) 17 (53.1%) 0.6c
Ocular signs 53 (86.9%) 28 (52.8%) 0.12c
Histopathology 32 (52.5%) 18 (56.2%) 0.85b
Autoantibodies anti-Ro/ antiLa 55 (90.2%) 31 (56.4%) 1c
pSS systemic manifestations
Whatever systemic manifestation 33 (54.1%) 23 (69.7%) 0.03b
Parotid enlargement 20 (32.8%) 15 (75%) 0.05b
Musculoskeletal involvement 29 (47.5%) 17 (58.62%) 0.85b
Skin involvement 14 (23%) 8 (57.14%) 0.98b
Renal involvement 0 0 -
Lung involvement 5 (8.2%) 2 (40%) 0.64c
Central nervous system involvement 1 (1.6%) 1 (100%) 1b
Peripheric nervous system involvement 2 (3.3%) 1 (50%) 1c
Hematological involvement 18 (29.5%) 10 (55.5%) 0.85b
Gastrointestinal involvement 3 (4.9%) 2 (66.7%) 1c
Cardiac involvement 0 0 -
pSS serological manifestations
RF+ 33 (54.1%) 19 (57.57%) 0.67b
ANA+ 56 (91.8%) 32 (57.14%) 1c
Modified immunoglobulins 36 (59%) 20 (55.55%) 0.73b
Values are number (%) of patients. RF, Rheumatoid Factor; ANA, Antinuclear autoantibodies. ªThe second column 
makes reference to how many patients with positive criteria or manifestation presented oral lesions, presented as number 
and percentage. Statistical test:  bChi-squared test or cFisher’s exact test.
Oral lesions pSS CG P
Number of patients with oral lesions (n, %) 35 (57.4%) 31 (25.4%) 0.0001a
Number of oral lesions (mean ± SD) 0.75±0.79 0.27±0.51 0.0001a
Types of oral lesions:
Traumatic lesions 8 (13.1%) 5 (4.1%) 0.03c
Oral candidiasis 8 (13.1%) 3 (2.5%) 0.007c
Denture stomatitis 5 (8.2%) 2 (1.6%) 0.04c
Angular cheilitis 3 (4.9%) 1 (0.8%) 0.10c
Median rhomboid glossitis 1 (1.6%) 0 0.33c
 Fissured tongue 5 (8.2%) 1 (0.8%) 0.02c
 Aphthae 5 (8.2%) 0 0.004c
 Coated tongue 4 (6.6%) 2 (1.6%) 0.09c
 Petechiae 2 (3.3%) 0 0.11c
 Depapillation of the tongue 2 (3.3%) 0 0.11c
 Diapneusia 2 (3.3%) 0 0.11c
 Geographic tongue 2 (3.3%) 1 (0.8%) 0.26c
 Melanocytic mole 1 (1.6%) 0 0.33c
 Labial herpes 1 (1.6%) 2 (1.6%) 1c
 Hyperkeratosis 1 (1.6%) 0 0.33c
 Desquamative gingivitis 1 (1.6%) 0 0.33c
 Lichen planus 1 (1.6%) 4 (3.3%) 0.66c
 Torus 0 6 (4.9%) 0.18c
 Fibroma 0 1 (0.8%) 1c
 Cheilitis of the lips 0 1 (0.8%) 1c
 Fistula 0 1 (0.8%) 1c
Values are number and %, and mean ± standard deviation (SD). Statistical test: aChi-squared test, bt-student test, and 
cFisher’s exact test
Table 2: pSS characteristics of the study group (n=61) according with the 2002 AECG and its relationship with oral 
lesions. pSS systemic and serological manifestations and its relationship with oral lesions.
Table 3: Types and number of oral lesions in pSS and CG.
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- Oral lesions as potential risk factors in pSS
No other relationships were observed between the rest 
of specific pSS variables (including time of diagnosis 
and onset of oral symptoms) and the presence of oral le-
sions, neither between other medical or pharmacologi-
cal features, tobacco, alcohol consumption, or use of 

















Male 0 1 (3.8%) 0.43c
Female 35 (100%) 25 (96.2%)







Diabetes 1 (2.9%) 2 (7.7%) 0.57c
Active smokers 6 (17.1%) 2 (7.7%) 0.45c
Number of cigarettes/day 1.029 ±3.72 0.38±1.76 0.27a
Alcohol 7 (20%) 6 (23.1%) 0.77b
Number of drugs 2.84±2.44 3±2.64 0.93a
Xerostomia inducing 
drugs
7 (21.9%) 9 (32.1%) 0.27c





7 (20%) 5 (80.8%) 0.94b
Antidepressant treatment 5 (14.3%) 2 (7.7%) 0.69c
Patients with dentures 9 (25.7%) 4 (15.4%) 0.33b
UWS hyposalivation 0.14b
Yes 24 (68.6%) 13 (50%)
No 11 (31.4%) 13 (50%)




Yes 20 (57.1%) 14 (53.8%)
No 15 (42.9%) 12 (46.2%)
SWS flow rate ml/min 
(mean±SD)
0.63±0.67 0.76±0.71 0.45a
Values are number (%) and mean ± standard deviation (SD). Statisti-
cal test:  aU-Mann-Whitney test, bFisher’s exact test and cChi-squared 
test. UWS: Unstimulated whole saliva, SWS: stimulated whole saliva.
Table 4: Differences between pSS patients with and without oral 
lesions. Relationship between hyposalivation, UWS and SWS flow 
rates and oral lesions.
- Oral lesions and oral symptoms in pSS
The relationship between oral symptoms and the pres-
ence of lesions was studied in pSS patients. A 94.3% of 
pSS patients with oral lesions also suffered dry mouth 
sensation, 42.3% dysphagia, 37.1% glossodynia and 
25.7% alteration in the taste of food. We did not find 
any statistical significance between having or not oral 
lesions and symptoms of oral discomfort, although xe-
rostomia (94.3% vs 88.5%, p=0.64) and glossodynia 
(37.1% vs 26.9%, p=0.42) was slightly higher in the 
group with oral lesions.
Discussion 
The present case-control study has shown that pSS pa-
tients are more likely to suffer from oral lesions than 
a matched CG, especially from candidiasis, traumatic 
lesions, aphthae and fissuration of the tongue. pSS pa-
tients with oral lesions had lower salivary flow levels 
and suffered more systemic manifestations and history 
of parotid gland enlargement than pSS patients without 
oral lesions.
SS is known to be one of the most common rheumatic dis-
eases. The lack of saliva could predispose to SS patients 
to suffer from some types of oral lesions such as coated 
tongue, atrophic mucosa or grooves or fissuration of the 
tongue (16). Additionally, people with SS seem to have 
an increased incidence of fungal infections. The pro-
cess of Candida colonization of oral tissues depends on 
different factors, including the interaction with salivary 
proteins. Saliva includes proteins such as histatins (anti-
fungal peptides), thus hyposalivation may not only alter 
the volume of saliva, but also the oral microflora and in-
crease the risk of opportunistic fungal infections (17,18).
Previous studies have reported the relationship 
between a reduction of salivary flow rates and Candida 
albicans counts in saliva (19,20), which sometimes 
could be associated with clinical signs of candidiasis 
(11,21,22,23,24). These studies have not established 
the relationship between salivary flow rates and other 
oral lesions apart from oral candidiasis. Only Pedersen 
et al., (12) described that oral mucosal changes (and 
not only candidiasis) occurred more frequently in 
pSS patients with lower salivary flow rates. To our 
knowledge, our study is the first to relate UWS and 
SWS with oral lesions in pSS patients. In our study, 
UWS and SWS hyposalivation and lower salivary 
flow rates were more frequently found in pSS patients 
with oral lesions although there were no statistically 
significant differences. In this sense, Lynge Pedersen et 
al., found that atrophic tongue and fissured tongue were 
associated with low UWS rates in a sample of older 
people in Copenhagen. This finding is in agreement 
with Bergdhal et al., that showed a relationship between 
the presence of oral lesions in a group of adult women 
and lower UWS flow rates (25,26).
Until date, only two studies have reported the full 
prevalence of oral lesions in SS patients. Patinen et al., 
found that 80% of SS patients presented some type of 
oral lesions compared to 40% of oral lesions in a group 
of patients with celiac disease. Likar-Manookin et al., 
reported a total percentage of 61.2% of oral lesions in 
a group of patients with pSS but they did not compare 
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it to a CG (10,11). In our study, 57.4% of pSS patients 
presented oral lesions vs 25.4% in the CG. In addition, 
pSS also suffered a higher number of oral lesions com-
pared with CG (0.75 vs 0.27). Our results are more simi-
lar to the ones obtained by Likar-Manookin et al., than 
to the results of Patinen et al., presumably due to the 
characteristics of the sample. Furthermore, our findings 
showed that pSS patients were 3.95 times more likely 
to suffer oral lesions than the CG. Until date, this is the 
first study that assessed this association.
A recent systematic review that analyses the presence 
of oral lesions in SS patients (27) has concluded that the 
most frequent oral lesions in these patients were angu-
lar cheilitis, atrophic glossitis, oral candidiasis, denture 
stomatitis, traumatic lesions, grooves of the tongue and 
atrophic mucosa. This is in accordance with what we 
found in the present study. The most common oral le-
sions found in pSS were oral candidiasis (13.1%), den-
ture stomatitis (8.2%), traumatic lesions (13.1%), apthae 
(8.2%), coated tongue (6.6%) and grooves or fissuration 
of the tongue (8.2%). This systematic review (27), em-
phasized that the included studies had some limitations, 
since most of them did not compare with a CG and al-
though some of them collected other potential risk fac-
tors (especially smoking habits, use of removable pros-
thesis and drugs intake) none of them related them to 
the presence of oral lesions. In this regard, we want to 
highlight that we took into account every possible lo-
cal factor that may be related to the onset of any oral 
lesions of any aetiology, although no significant differ-
ences were found. Likar-Manookin et al., reported that 
they did not find any relationship between drugs intake 
and the presence of autoimmune oral lesions; neither 
did we in our present study. Some authors suggested 
that denture wearing should be taken as a predisposing 
factor for suffering from oral fungal infection (angular 
cheilitis and denture-induced stomatitis) and oral ulcers 
in SS patients (24,28), although, other studies (9) did not 
find significant differences when compared to a CG, as 
the present study did.
Likar-Manookin et al., reported a prevalence of 12% 
of autoimmune oral lesions in a cohort of pSS patients. 
They found a prevalence of 7.1% of lichen planus and 
3.9% of recurrent aphthous stomatitis. In our study, 
we have found the same two oral lesions of possible 
autoimmune aetiology, lichen planus (1.6%) and apthous 
stomatitis (8.2%) (11). The number of each oral lesion 
differs between the studies, but as Likar-Mannokin 
et al., suggested we though that pSS and autoimmune 
oral lesions might have a common aetiology due to 
a hyperactive autoimmune response. pSS patients 
with systemic involvement are considered to have 
a more aggressive type of pSS with a higher risk of 
morbidity, mortality, cardiovascular and hospitalization 
risk (29). For this reason, the heterogeneity of SS has 
been emphasized in the past years, highlighting the 
importance of the early identification of both glandular 
and extraglandular manifestations. To date, this is the 
first study that has evaluated the relationship between 
oral lesions and different pSS clinical variables 
and potential predisposing factors such as disease 
progression or time from diagnosis besides all the 
possible systemic manifestations. Other authors 
(14,17,21,23) collected the time from diagnosis and 
mean duration of the disease, but did not correlate them 
with the presence of oral lesions. Indeed, we have found 
that those patients with systemic manifestations and/or 
previous parotid enlargement had a higher prevalence 
of oral lesions, which could be related with a higher 
activity of the disease. In our opinion, patients with pSS 
systemic involvement should frequently attend to both 
their medical and dental check-ups, in order to prevent 
possible oral complications.
Our study has also attempted to find if there was a re-
lationship between oral symptoms and the presence of 
oral lesions in pSS patients. Almost 95% of pSS patients 
with oral lesions also suffered from dry mouth sensa-
tion, 42.3% dysphagia, 37.1% glossodynia and 25.7% 
alteration in the taste of food. These results are in accor-
dance with the study of Marton et al., who reported xe-
rostomia in 91.8%, glossodynia in 38.7% and dysphagia 
in 35% of SS patients (9). Although we did not find any 
statistically significance between having or not oral le-
sions and oral symptoms of discomfort, xerostomia and 
glossodynia, the symptoms were slightly higher in the 
group with oral lesions. Marton et al., obtained similar 
results in their SS patients, 50% of those with candidia-
sis suffered from glossodyinia as well.
One of the limitations of this study was the number of 
participants. pSS patients were referred from the differ-
ent rheumatology services but not all of them attended 
to the school of dentistry. Another limitation was the 
study design because our study is a cross-sectional 
study. It is necessary to carry out future longitudinal 
studies where patients could be assessed at different 
times, looking for possible oral lesions, salivary flow 
rates and oral symptoms, and its possible relationship 
both with systemic and local factors.
In conclusion, this study shows that pSS patients were 
more likely to suffer oral lesions than the CG. Oral le-
sions seem to be more frequent in those pSS patients 
with systemic manifestations and especially with previ-
ous parotid involvement. Due to the heterogeneity and 
complexity of the disease it is necessary to highlight the 
importance that pSS patients should be managed by a 
multidisciplinary team including at least rheumatolo-
gists, ophthalmologists and dentists. Dentist should be 
aware of the risk of suffering oral lesions of these pa-
tients, probably related to the lower levels of saliva. Be-
sides, these oral lesions usually do not produce symp-
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toms so frequent check-up appointments are necessary 
to diagnose them. Future follow-up longitudinal stud-
ies with larger number of pSS patients, and where the 
whole oral lesions are taken into account are necessary 
to establish the relationship between oral lesions and 
different features of pSS patients.
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María Carmen Ortega (Hospital Infanta Elena), Diana Peiteado 
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